Particle.news
Download on the App Store

First Human Trial Finds Enteral Ventilation Safe in Healthy Volunteers

Researchers will next test oxygenated perfluorodecalin in hypoxemic patients to evaluate oxygen transfer.

Overview

  • Results published in Med report that intrarectal perfluorodecalin was well tolerated in 27 healthy men, with only mild, transient gastrointestinal symptoms.
  • Doses up to 1,000 mL were delivered in an enema-like procedure, vital signs remained stable, and no serious adverse events were observed.
  • The study used non-oxygenated fluid in non-hypoxemic participants, so efficacy for raising blood oxygen was not measured.
  • Investigators are preparing Phase II trials in Japan and the United States to assess whether oxygenated perfluorodecalin can improve oxygenation in patients with low blood oxygen.
  • Developers position the approach as a complementary bridge for severe respiratory compromise, drawing on earlier animal studies that showed benefit.